Results
5
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
5 companies
argenx
Market Cap: €28.6b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€467.10
7D
-2.5%
1Y
16.0%
Elia Group
Market Cap: €10.7b
Develops and operates as a transmission system operator in Belgium and Germany.
ELI
€98.30
7D
0.6%
1Y
9.4%
Groupe Bruxelles Lambert
Market Cap: €8.6b
Invests in a portfolio of industrial, consumer goods, and business service companies operating in various sectors in Belgium, other European countries, North America, and internationally.
GBLB
€72.55
7D
-0.5%
1Y
6.0%
UCB
Market Cap: €32.1b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€168.90
7D
-0.8%
1Y
18.3%
D'Ieteren Group
Market Cap: €9.7b
Operates as an investment company in Belgium, France, rest of Europe, and internationally.
DIE
€183.80
7D
2.6%
1Y
-11.0%